Paradigm Biopharmaceuticals (ASX:PAR) has marked 2025 as a transformative year, moving from regulatory preparation to the active execution of its global Phase 3 clinical trial for iPPS (Zilosul) in knee osteoarthritis, while also strengthening its financial foundations and broadening its treatment pipeline. …
Adherium pushes ahead with US expansion and stronger commercial focus
August 31, 2025 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News